Thymalin
Thymulin, Thymic Factor, Serum Thymic Factor, Facteur Thymique Serique
Unknown
PHASE2
INTERVENTIONAL
NCT04517539
Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) and Peginterferon alfa-2b is safe, effective in the treatment of patients with metastatic thymic epithelial tumors.
Interventions
Name:
rhGM-CSF，Peginterferon alfa-b2，radiation
Type:
DRUG
Description:
Radiation:
If there are two measurable lesions totally, One lesion received radiotherapy for 30 Gy in 5 fractions and rested for one week; If there are three measurable lesions totally, two lesion received radiotherapy for 30 Gy in 5 fractions separately.
drug: Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy. Peginterferon alfa-b2 90 ug in d8 in each cycle.
And the 1 month after the end of all radiotherapy courses, 4 weeks as a course of treatment, once per course of treatment, each dose is 90μg until desease progress.
Primary Outcomes
Measure:
The abscopal effect rate
TimeFrame:
up to 12 months
Description:
The proportion of patients with an abscopal response assessed after the initiation of treatment
Trial Information
NCT ID
NCT04517539
Status
Unknown
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Shanghai Cancer Hospital, China
Last Updated
December 15, 2025